Role of p53 assessment in management of Barrett's esophagus.
The risk of developing gastroesophageal adenocarcinoma is increased in patients with Barrett's esophagus. The management of dysplasia in Barrett's esophagus remains controversial. Understanding of the sequence of events preceding malignancy is essential before screening protocols for early diagnosis and preventive measures can be implemented. The aim of this review is to examine the published data on the role p53 assessment may play in the management of Barrett's esophagus. Relevant papers were identified by an extensive text word search of the Medline database and a review of quoted articles. The p53 abnormality occurs more frequently in highly dysplastic epithelium than in nondysplastic epithelium. However, the retrospective nature of most of the available data could be a significant confounding factor. Our current knowledge suggests that p53 protein overexpression does not seem to predict future progression to cancer or determine disease outcome. The p53 abnormality alone can not be reliably used to predict progression of Barrett's esophagus to cancer. We must await long-term evaluation of patients to determine the percentage of patients with p53 gene abnormality, and nondysplastic Barrett's who will progress to dysplasia or carcinoma. Large randomized controlled long-term follow-up studies are much needed.
Kubba
A K
AK
Department of Surgery, North Manchester General Hospital, University of Manchester, UK.
Poole
N A
NA
Watson
A
A
D000230:Adenocarcinoma / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D001471:Barrett Esophagus / Q000150:complications / Q000235:genetics* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000235:genetics*; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D018570:Risk Assessment
D014408:Biomarkers, Tumor